Impact of refitted race-free eGFR formula on obesity pharmacotherapy options.
Impact of refitted race-free eGFR formula on obesity pharmacotherapy options.
复制标题
DOI：
10.1002/oby.23542
复制
发表时间：
2022-11
期刊：
影响因子：
--
通讯作者：
中科院分区：
文献类型：
--
作者：
Recent changes to the Chronic Kidney Disease Epidemiology Collaboration estimated glomerular filtration rate (eGFR) formula (2021 CKD-EPI) removed race from the 2009 formula, increasing the number of Black people classified as having CKD, but these changes may impact eligibility and/or dosing for antiobesity medications. This study estimated the number of people with obesity nationwide who might have pharmacotherapy options impacted by the new formula. Using National Health and Nutrition Examination Survey (NHANES) cohort study data, the number of people eligible for antiobesity medication was estimated, and the number who would require a dosage reduction or would no longer be eligible for specific medications based on the new eGFR formula was also estimated. Among 16,412,571 Black and 109,654,751 non-Black people eligible for antiobesity medication, 911,336 (6.1%) Black and 6,925,492 (6.6%) non-Black people had ≥CKD stage 3 by the 2009 CKD-EPI formula. Applying the 2021 CKD-EPI formula, 1,260,969 (8.5%) Black people and 4,989,919 (4.7%) non-Black people had ≥CKD stage 3. For medications requiring renal adjustment, the number of Black people who would require a lower dose or be precluded from using a medication increased by 24.7% to 50.2%. These findings highlight the importance of measuring—rather than estimating—GFR in Black people with CKD when considering many antiobesity pharmacotherapy options.
登录
查看更多内容
影响因子：
2.8
作者：
Haughton CF;Silfee VJ;Wang ML;Lopez-Cepero AC;Estabrook DP;Frisard C;Rosal MC;Pagoto SL;Lemon SC
通讯作者：
Lemon SC
DOI：
10.1053/j.ajkd.2008.05.023
发表时间：
2008-10
期刊：
American journal of kidney diseases : the official journal of the National Kidney Foundation
影响因子：
--
作者：
Accetta NA;Gladstone EH;DiSogra C;Wright EC;Briggs M;Narva AS
通讯作者：
Narva AS
影响因子：
158.5
作者：
Kelly, Aaron S.;Auerbach, Pernille;Arslanian, Silva
通讯作者：
Arslanian, Silva
DOI：
10.1056/nejmoa1603827
发表时间：
2016-07-28
期刊：
The New England journal of medicine
影响因子：
--
作者：
Marso SP;Daniels GH;Brown-Frandsen K;Kristensen P;Mann JF;Nauck MA;Nissen SE;Pocock S;Poulter NR;Ravn LS;Steinberg WM;Stockner M;Zinman B;Bergenstal RM;Buse JB;LEADER Steering Committee;LEADER Trial Investigators
通讯作者：
LEADER Trial Investigators
影响因子：
4.2
作者：
Diaz-Lopez, Andres;Becerra-Tomas, Nerea;Salas-Salvado, Jordi
通讯作者：
Salas-Salvado, Jordi